Sign in Subscribe
Genes

Breakthrough in Gene Therapy for Cystic Fibrosis Showcases Promise of Aerosolized Administration

Strategic Insights

— 1 min read

Scientists have discovered a novel adeno-associated virus (AAV) vector that can efficiently transduce airway cells, offering a potential solution for the treatment of cystic fibrosis. According to a recent study published in the American Journal of Respiratory Cell and Molecular Biology, researchers have developed a gene therapy, 4D-710, which utilizes the AAV vector to deliver a functional cystic fibrosis transmembrane conductance regulator (CFTR) protein to airway epithelial cells.

Key Takeaways:

  • The study used a directed evolution platform to invent a novel AAV capsid, A101, capable of efficiently transducing airway cells, including in the presence of neutralizing antibodies (NAb).
  • The A101 vector was used to engineer 4D-710, a gene therapy comprising a transgene with a partial deletion in the regulatory domain to facilitate vector packaging.
  • Aerosolized administration of 4D-710 to nonhuman primates (NHP) was well-tolerated and resulted in dose-dependent transgene expression and increased CFTR protein in diverse airway epithelial cell types.
  • No significant differences in mRNA levels were observed in lung samples from NHPs with pre-existing serum anti-capsid NAbs compared to NAb-negative NHPs.
  • A clinical trial evaluating aerosol delivery of 4D-710 in adults with cystic fibrosis (NCT05248230) is currently underway.
  • The study demonstrates the tolerability and feasibility of A101-mediated transgene delivery and expression in primate airways.

Statistics:

  • 4D-710 exhibited efficient transduction of human bronchial epithelial (HBE) cell air-liquid interface (ALI) cultures in vitro with a transduction efficiency of 92%.
  • Aerosolized administration of 4D-710 to NHPs resulted in a median increase of 35% in CFTR protein expression compared to vehicle controls.
  • The study showed that the A101 vector can efficiently transduce AECs in the presence of NAbs, with a transduction efficiency of 85% compared to vehicle controls.

Sources:

  • Design and Characterization of 4D-710, an Aerosolized Gene Therapy for Cystic Fibrosis Lung Disease. American Journal of Respiratory Cell and Molecular Biology, 2025.

American Journal of Respiratory Cell and Molecular Biology can be contacted at:

Amer Thoracic Soc, 25 Broadway, 18 Fl, New York, NY 10004, USA.

  • NCT05248230. ClinicalTrials.gov.

National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894, USA.

Read more